Telix Pharmaceuticals (Est) Pty. Ltd.
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, is a pioneering biopharmaceutical company focused on the development of innovative cancer therapies and diagnostic imaging solutions. Founded in 2015, Telix has rapidly established itself in the oncology sector, with a strong emphasis on radiopharmaceuticals that target specific cancer types. The company operates primarily in Australia, Europe, and North America, offering unique products such as TLX591 (a prostate cancer imaging agent) and TLX250 (for renal cancer). These therapies leverage advanced radiolabelled technology, setting Telix apart in a competitive market. With a commitment to improving patient outcomes, Telix Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of targeted cancer treatment.
DitchCarbon Score
How does Telix Pharmaceuticals (Est) Pty. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals (Est) Pty. Ltd.'s score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Telix Pharmaceuticals (Est) Pty. Ltd.'s reported carbon emissions
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how Telix Pharmaceuticals is addressing climate change or contributing to sustainability efforts within the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Telix Pharmaceuticals (Est) Pty. Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
